%0 Journal Article
%T GnRH-A在不同卵巢功能患者超排中应用的研究进展
%A 闫桂敏
%A 王炎秋
%A 综述
%A 纪亚忠
%J 同济大学学报(医学版)
%D 2017
%R 10.16118/j.1008-0392.2017.01.027
%X 目前,国内辅助生殖技术中控制性超促排卵(controlled ovarian hyperstimulation, COH)仍以促性腺激素释放激素激动剂(gonadotropin releasing hormone agonist, GnRH-a)长方案为主,但GnRH-a长方案中的大剂量、长时间的促性腺激素(gonadotropin,Gn)暴露对卵泡的生长、卵子的发育不利。20世纪90年代,促性腺激素释放激素拮抗剂(gonadotropin releasing hormone antagonist, GnRH-A)开始用于人类辅助生殖技术(assisted reproductive technology, ART)。GnRH-A通过与垂体促性腺激素释放激素(gonadotropin releasing hormone, GnRH)受体结合,有效抑制早发黄体生成素(luteinizing hormone, LH)峰,具有起效快、作用时间短、停药后垂体恢复迅速等特点,然而其在不同卵巢功能患者超排中的应用尚存在争议。本文对GnRH-A在ART中的临床应用作一综述。</br>Gonadotropin-releasing hormone agonists(GnRH-a)are widely used in controlled ovarian hyperstimulation (COH) at present in China. However, more and more studies show that long-term and large dose administration of GnRH-a would have an adverse effects on oocytes. Gonadotropin-releasing hormone antagonists (GnRH-A) have been used in human assisted reproduction technology (ART) since 1990s. As a competitive inhibitor of gonadotropin-releasing hormone (GnRH) receptors, GnRH-A can prevent the premature luteinizing hormone (LH) surge during COH, and GnRH-A has the advantages of fast action, short action duration and quick piruitary recovery. But it is controversial to use GnRH-A in patients with different ovarian responses. In this article, we will review the clinical application of GnRH-A in ART, focusing on its use in patients with different ovarian function
%K 促性腺激素释放激素拮抗剂 人类辅助生殖技术 控制性超促排卵&lt
%K /br&gt
%K gonadotropin-releasing hormone antagonist human assisted reproduction technology controlled ovarian hyperstimulation
%U http://tjyxxb.cnjournals.cn/ch/reader/view_abstract.aspx?file_no=20170127&flag=1